




Pancreatic Cancer Action Network

Independent Auditor's Report and Financial Statements

June 30, 2025 and 2024



Pancreatic Cancer Action Network
Contents
June 30, 2025 and 2024

Independent Auditor’s Report.....	1
Financial Statements	
Statements of Financial Position.....	3
Statement of Activities – 2025.....	4
Statement of Activities – 2024.....	5
Statement of Functional Expenses – 2025	6
Statement of Functional Expenses – 2024	7
Statements of Cash Flows	8
Notes to Financial Statements	9

Independent Auditor's Report

Board of Directors
Pancreatic Cancer Action Network
El Segundo, California

Opinion

We have audited the financial statements of Pancreatic Cancer Action Network, which comprise the statements of financial position as of June 30, 2025 and 2024, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Pancreatic Cancer Action Network as of June 30, 2025 and 2024, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Pancreatic Cancer Action Network and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Pancreatic Cancer Action Network's ability to continue as a going concern within one year after the date that these financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Pancreatic Cancer Action Network's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Pancreatic Cancer Action Network's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Forvis Mazars, LLP

New York, New York
October 24, 2025

Pancreatic Cancer Action Network
Statements of Financial Position
June 30, 2025 and 2024

	2025	2024
ASSETS		
Cash and cash equivalents	\$ 3,697,011	\$ 7,781,023
Investments	18,239,542	30,065,485
Pledges receivable, net	11,949,001	14,002,396
Receivables	435,868	128,847
Contracts in progress	-	92,321
Prepaid expenses	1,370,809	2,451,294
Property and equipment, net	594,388	649,515
Right-of-use asset – operating lease	4,121,270	892,450
Other assets	617,671	210,502
Total Assets	\$ 41,025,560	\$ 56,273,833
LIABILITIES AND NET ASSETS		
Liabilities		
Accounts payable and accrued liabilities	\$ 1,815,827	\$ 8,703,327
Accrued wages and benefits	2,124,108	2,299,669
Grant obligations, net	2,224,854	7,586,327
Deferred revenue	30,540	1,144,084
Operating lease liability	4,306,915	1,327,453
Total Liabilities	10,502,244	21,060,860
Net Assets (Deficit)		
Without donor restrictions		
Undesignated	3,038,681	(808,592)
Board-designated operating reserve	11,650,000	17,090,000
Net Assets Without Donor Restrictions	14,688,681	16,281,408
With donor restrictions	15,834,635	18,931,565
Total Net Assets	30,523,316	35,212,973
Total Liabilities and Net Assets	\$ 41,025,560	\$ 56,273,833

Pancreatic Cancer Action Network
Statement of Activities
Year Ended June 30, 2025

	2025		
	Without Donor Restrictions	With Donor Restrictions	Total
Operating Revenues, Gains, and Other Support			
Contributions	\$ 16,118,787	\$ 6,641,463	\$ 22,760,250
Special events income (net of direct costs of \$3,404,913)	14,101,498	-	14,101,498
Clinical research contracts	3,550,566	-	3,550,566
Contributed nonfinancial assets	574,491	-	574,491
Other income (loss)	(22,402)	-	(22,402)
Net assets released from restrictions	9,738,393	(9,738,393)	-
Total Operating Revenues, Gains, and Other Support	44,061,333	(3,096,930)	40,964,403
Operating Expenses			
Program Services			
Research and Scientific Affairs	13,822,863	-	13,822,863
Advocacy	971,774	-	971,774
Patient services	4,670,773	-	4,670,773
Community engagement	6,917,114	-	6,917,114
Total Program Services	26,382,524	-	26,382,524
Support Services			
Management and administration	15,505,232	-	15,505,232
Development	6,128,718	-	6,128,718
Total Support Services	21,633,950	-	21,633,950
Total Operating Expenses	48,016,474	-	48,016,474
Change in Net Assets from Operations	(3,955,141)	(3,096,930)	(7,052,071)
Nonoperating Activities			
Investment return	1,954,019	-	1,954,019
Miscellaneous Income	20,000	-	20,000
Gain on termination of lease	388,395	-	388,395
Change in Net Assets	(1,592,727)	(3,096,930)	(4,689,657)
Net Assets, Beginning of Year	16,281,408	18,931,565	35,212,973
Net Assets, End of Year	\$ 14,688,681	\$ 15,834,635	\$ 30,523,316

Pancreatic Cancer Action Network
Statement of Activities
Year Ended June 30, 2024

	2024		
	Without Donor Restrictions	With Donor Restrictions	Total
Operating Revenues, Gains, and Other Support			
Contributions	\$ 17,183,104	\$ 5,742,364	\$ 22,925,468
Special events income (net of direct costs of \$3,320,870)	13,437,790	-	13,437,790
Clinical research contracts	8,510,939	-	8,510,939
Contributed nonfinancial assets	130,035	-	130,035
Other income	20,799	-	20,799
Net assets released from restrictions	10,737,050	(10,737,050)	-
Total Operating Revenues, Gains, and Other Support	50,019,717	(4,994,686)	45,025,031
Operating Expenses			
Program Services			
Research and Scientific Affairs	27,231,139	-	27,231,139
Advocacy	1,136,745	-	1,136,745
Patient services	4,788,744	-	4,788,744
Community engagement	7,937,565	-	7,937,565
Total Program Services	41,094,193	-	41,094,193
Support Services			
Management and administration	12,720,419	-	12,720,419
Development	6,679,797	-	6,679,797
Total Support Services	19,400,216	-	19,400,216
Total Operating Expenses	60,494,409	-	60,494,409
Change in Net Assets from Operations	(10,474,692)	(4,994,686)	(15,469,378)
Nonoperating Activities			
Investment return	1,861,915	-	1,861,915
Change in Net Assets	(8,612,777)	(4,994,686)	(13,607,463)
Net Assets, Beginning of Year	24,894,185	23,926,251	48,820,436
Net Assets, End of Year	\$ 16,281,408	\$ 18,931,565	\$ 35,212,973

Pancreatic Cancer Action Network
Statement of Functional Expenses
Year Ended June 30, 2025

	Program Services					Support Services			Total Expenses
	Research and Scientific Affairs	Advocacy	Patient Services	Community Engagement	Total Program Services	Management and Administration	Development	Total Supporting Services	
Salaries	\$ 4,636,946	\$ 596,314	\$ 2,461,190	\$ 3,128,362	\$ 10,822,812	\$ 5,811,859	\$ 2,955,056	\$ 8,766,915	\$ 19,589,727
Payroll taxes and benefits	1,061,669	137,253	566,514	718,341	2,483,777	1,229,295	680,132	1,909,427	4,393,204
Research	6,494,139	-	-	-	6,494,139	-	-	-	6,494,139
Conferences, workshops, and travel	261,350	15,515	4,406	298,760	580,031	179,497	69,074	248,571	828,602
Professional fees	792,489	159,341	852,404	1,360,999	3,165,233	2,813,227	1,342,720	4,155,947	7,321,180
Advertising	-	4,783	351,813	771,298	1,127,894	122,174	368,939	491,113	1,619,007
Donor and affiliate engagement	20	-	-	169,319	169,339	2,745	259,868	262,613	431,952
Dues and subscriptions	20,006	19,539	-	2,000	41,545	14,369	9,340	23,709	65,254
Occupancy and maintenance	113,673	17,176	134,049	124,395	389,293	177,696	99,137	276,833	666,126
Finance and processing charges	-	-	-	-	-	1,085,304	-	1,085,304	1,085,304
Bad debt expense	-	-	-	-	-	2,000,000	-	2,000,000	2,000,000
Information technology	195,563	16,852	109,887	164,503	486,805	1,415,416	261,742	1,677,158	2,163,963
Insurance	184,924	-	-	83,741	268,665	194,233	-	194,233	462,898
Postage, printing, and supplies	125	-	142,094	15,079	157,298	59,756	49,702	109,458	266,756
Staff support	1,789	-	9,376	44,256	55,421	351,253	4,108	355,361	410,782
Depreciation	60,170	5,001	39,040	36,061	140,272	48,408	28,900	77,308	217,580
Totals	\$ 13,822,863	\$ 971,774	\$ 4,670,773	\$ 6,917,114	\$ 26,382,524	\$ 15,505,232	\$ 6,128,718	\$ 21,633,950	\$ 48,016,474

Pancreatic Cancer Action Network
Statement of Functional Expenses
Year Ended June 30, 2024

	Program Services					Support Services			Total Expenses
	Research and Scientific Affairs	Advocacy	Patient Services	Community Engagement	Total Program Services	Management and Administration	Development	Total Supporting Services	
Salaries	\$ 5,287,087	\$ 750,851	\$ 2,860,411	\$ 4,075,577	\$ 12,973,926	\$ 6,033,165	\$ 3,928,081	\$ 9,961,246	\$ 22,935,172
Payroll taxes and benefits	1,092,361	155,612	588,853	847,738	2,684,564	1,185,303	820,974	2,006,277	4,690,841
Research	18,819,843	-	-	-	18,819,843	-	-	-	18,819,843
Conferences, workshops, and travel	310,734	3,284	328	360,297	674,643	196,369	74,702	271,071	945,714
Professional fees	1,075,101	162,204	569,899	1,229,499	3,036,703	2,394,082	991,460	3,385,542	6,422,245
Advertising	-	-	326,969	832,463	1,159,432	86,051	223,313	309,364	1,468,796
Donor and affiliate engagement	-	-	-	162,042	162,042	7,653	184,237	191,890	353,932
Dues and subscriptions	21,205	18,916	-	-	40,121	7,649	121	7,770	47,891
Occupancy and maintenance	108,541	20,667	129,830	135,228	394,266	159,959	106,025	265,984	660,250
Finance and processing charges	-	-	-	-	-	780,374	-	780,374	780,374
Information technology	231,441	16,603	109,022	163,858	520,924	1,117,747	265,974	1,383,721	1,904,645
Insurance	193,484	-	-	52,369	245,853	198,159	-	198,159	444,012
Postage, printing, and supplies	232	-	160,725	29,026	189,983	55,443	47,252	102,695	292,678
Staff support	21,350	4,084	13,659	19,424	58,517	465,414	13,936	479,350	537,867
Depreciation	69,760	4,524	29,048	30,044	133,376	33,051	23,722	56,773	190,149
Totals	\$ 27,231,139	\$ 1,136,745	\$ 4,788,744	\$ 7,937,565	\$ 41,094,193	\$ 12,720,419	\$ 6,679,797	\$ 19,400,216	\$ 60,494,409

Pancreatic Cancer Action Network
Statements of Cash Flows
Years Ended June 30, 2025 and 2024

	<u>2025</u>	<u>2024</u>
Operating Activities		
Change in net assets	\$ (4,689,657)	\$ (13,607,463)
Adjustments to reconcile change in net assets to net cash from operating activities		
Depreciation and amortization	217,580	190,149
Bad debt expense	2,000,000	-
Investment gain	(1,954,019)	(1,861,915)
Gain on termination of lease	(388,395)	-
Provision (gain) for uncollectible pledges	148,503	(170,518)
Noncash operating lease expense	419,040	510,460
Changes in operating assets and liabilities		
Pledges receivable	1,904,892	9,141,051
Receivables	(2,214,700)	9,023,403
Prepaid expenses	1,080,485	1,143,547
Other assets	(407,169)	41,982
Accounts payable and accrued expenses	(6,887,500)	(2,977,262)
Accrued wages and benefits	(175,561)	(204,286)
Grant obligations	(5,361,473)	(5,429,451)
Deferred revenue	(1,113,544)	69,183
Operating lease liability	(280,003)	(685,642)
Net Cash Used in Operating Activities	<u>(17,701,521)</u>	<u>(4,816,762)</u>
Investing Activities		
Purchase of investments	(4,459,580)	(24,801,923)
Purchase of sale of investments	18,239,542	30,065,485
Purchase of property and equipment	(162,453)	(506,369)
Net Cash Provided by Investing Activities	<u>13,617,509</u>	<u>4,757,193</u>
Financing Activities		
Principal payments on finance lease obligations	-	(8,946)
Net Cash Used in Financing Activities	<u>-</u>	<u>(8,946)</u>
Change in Cash and Cash Equivalents	(4,084,012)	(68,515)
Cash and Cash Equivalents, Beginning of Year	<u>7,781,023</u>	<u>7,849,538</u>
Cash and Cash Equivalents, End of Year	<u>\$ 3,697,011</u>	<u>\$ 7,781,023</u>
Supplemental Cash Flows Information		
Operating lease modification resulting in reduction of right-of-use asset and lease liability	\$ -	\$ 1,482,672
Right-of-use assets obtained in exchange for new operating lease liabilities	\$ 4,448,697	\$ -

Note 1. Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

The Pancreatic Cancer Action Network (PanCAN), was founded in 1999. PanCAN's vision is to create a world in which all patients with pancreatic cancer will thrive. Our mission is to take bold action to improve the lives of everyone impacted by pancreatic cancer by advancing scientific research, building community, sharing knowledge, and advocating for patients. PanCAN has a comprehensive approach to fighting pancreatic cancer that includes funding transformative research, providing patient services, advocating for increased federal research dollars, and educating the public and raising awareness about pancreatic cancer.

PanCAN funds research—everything from early detection to innovative new treatment approaches. PanCAN's cumulative research investment is now \$249 million, making a significant impact on the diagnosis and treatment of today's patients and those who will be diagnosed in the future. PanCAN also advocates for increased federal research funding for pancreatic cancer researchers across the country to accelerate progress and continues to grow the number of researchers focused on this disease. PanCAN Patient Services provides free, personalized information and resources about pancreatic cancer, in English and in Spanish, including treatment options, clinical trials, genetic and biomarker testing and supportive care resources. Through PanCAN Patient Services, PanCAN talks to more patients with pancreatic cancer and caregivers than any other organization in the world. Through its nearly 55 volunteer-led Affiliates across the country, PanCAN and local communities work together to educate and raise awareness and funds to accelerate progress for patients with pancreatic cancer.

PanCAN raises most of its revenue from individual and corporate contributions, including those made through PanCAN PurpleStride events. PanCAN moved its headquarters to El Segundo, California from Manhattan Beach, California in September 2024.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues, expenses, gains, losses, and other changes in net assets during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

PanCAN considers all liquid investments with original maturities of three months or less to be cash equivalents. Uninvested cash and cash equivalents included in investment accounts are not considered to be cash and cash equivalents. At June 30, 2025 and 2024, cash equivalents consisted primarily of money market funds.

At times during the year, PanCAN may hold deposits in excess of federal depository insurance limits, resulting in a concentration of credit risk. At June 30, 2025 and 2024, and throughout both years, PanCAN kept cash deposits at a financial institution that are in excess of the federal depository insurance limits.

Accounts Receivable

Accounts receivable are stated at the amount of consideration from pharmaceutical and research organizations for design and management of clinical trial research. Receivables are recognized only to the extent that PanCAN has an unconditional right to consideration to which it is entitled in exchange for services performed. Receipts received in advance of services performed are recorded as deferred revenue. PanCAN provides an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. Delinquent receivables are written off based on individual credit evaluation and specific circumstances of the customer.

Contracts in Progress

Contracts in progress are recorded when PanCAN has a right to consideration in exchange for goods or services that PanCAN has transferred to the customer. PanCAN records a contract asset for the prorated amount of work performed through the end of the year, but payment is not yet due from the customer.

Inventories

Inventories consist of various promotional items that are held for sale. Inventories are stated at the lower of cost or market using the first-in, first-out (FIFO) method. Inventories are included in other assets on the accompanying statements of financial position. At June 30, 2025 and 2024, inventories were \$0 and \$21,439, respectively.

Investments and Net Investment Return

PanCAN measures securities at fair value. Investment return includes dividend, interest, and other investment income; realized and unrealized gains and losses on investments carried at fair value; and realized gains and losses on other investments, less external and direct internal investment expenses. Gains and losses on the sale of securities are recorded on the trade date and are determined using the specific identification method.

Investment return that is initially restricted by donor stipulation and for which the restriction will be satisfied in the same year is recorded as with donor restrictions and then released from restriction. Other investment return is reflected in the statements of activities with or without donor restrictions based upon the existence and nature of any donor or legally imposed restrictions.

Property and Equipment

Property and equipment acquisitions over \$5,000 are stated at cost less accumulated depreciation and consist of prepaid leasehold improvements, furniture and fixtures associated with the administrative offices, database systems and website, and computers and software. PanCAN also capitalizes a group of assets purchased in bulk, if those bulk items are over \$10,000.

Depreciation is charged to expense using the straight-line method over the estimated useful lives of each asset. Estimated useful lives for furniture and equipment, computer software, and internally developed asset costs are 3 to 10 years. Assets under leasehold improvements are depreciated over the shorter of the lease term or their respective estimated useful lives.

Long-Lived Asset Impairment

PanCAN evaluates the recoverability of the carrying value of long-lived assets whenever events or circumstances indicate the carrying amount may not be recoverable. If a long-lived asset is tested for recoverability and the undiscounted estimated future cash flows expected to result from the use and eventual disposition of the asset are less than the carrying amount of the asset, the asset cost is adjusted to fair value and an impairment loss is recognized as the amount by which the carrying amount of a long-lived asset exceeds its fair value.

No asset impairment was recognized during the years ended June 30, 2025 and 2024.

Grant Obligations

PanCAN awards peer-reviewed research grants to investigators who are devoted to scientific research related to pancreatic cancer. Research grants may include multi-year installment payments. As a compliance requirement, PanCAN requires periodic reporting on the research activities associated with the grant award. In addition, grant agreements for the Precision Promise and Early Detection Initiative programs have been included in grant obligations. Grants and fees are recognized as expense when the grant is awarded to a named recipient. Grants with payment terms in excess of one year from the fiscal year-end are discounted to the present value of the obligation using a risk-free treasury rate applicable to the day in which the obligation is made.

Deferred Revenue

Revenue from fees for clinical trials is deferred and recognized over the periods to which the fees relate.

Net Assets

Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor restrictions.

Net assets without donor restrictions are available for use in general operations and not subject to donor or certain grantor restrictions.

PanCAN defines Board Designated Operating Reserve as the portion of net assets without donor restrictions that have been designated for use in emergencies and to sustain financial operations in the event budgeted revenue is not realized or unforeseen expenses are incurred. The presence of an operating reserve provides PanCAN with flexibility to respond adeptly to rapidly changing economic and other conditions that warrant an immediate shift in strategy. The Board has established a target of maintaining a minimum, fully funded operating reserve sufficient to fund four months of budgeted operating costs. At June 30, 2025 and 2024, the Board Designated Operating Reserve balance was \$11,650,000 and \$17,090,000, respectively, and represented approximately four months of fiscal operating expense.

Net assets with donor restrictions are subject to donor or certain grantor restrictions. Some restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor.

Contributions

Contributions are provided to PanCAN either with or without restrictions placed on the gift by the donor. Revenues and net assets are separately reported to reflect the nature of those gifts—with or without donor restrictions. The value recorded for each contribution is recognized as follows:

Nature of the Gift	Value Recognized
<i>Conditional gifts, with or without restriction</i>	
Gifts that depend on PanCAN overcoming a donor-imposed barrier to be entitled to the funds	Not recognized until the gift becomes unconditional, <i>i.e.</i> , the donor-imposed barrier is met
<i>Unconditional gifts, with or without restriction</i>	
Received at date of gift – cash and other assets	Fair value
Received at date of gift – property, equipment, and long-lived assets	Estimated fair value
Expected to be collected within one year	Net realizable value
Collected in future years	Initially reported at fair value determined using the discounted present value of estimated future cash flows technique

In addition to the amount initially recognized, revenue for unconditional gifts to be collected in future years is also recognized each year as the present-value discount is amortized using the level-yield method.

When a donor-stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions. Absent explicit donor stipulations for the period of time that long-lived assets must be held, expirations of restrictions for gifts of land, buildings, equipment, and other long-lived assets are reported when those assets are placed in service.

Pancreatic Cancer Action Network
Notes to Financial Statements
June 30, 2025 and 2024

Gifts and investment income that are originally restricted by the donor and for which the restriction is met in the same time period the gift is received are recorded as revenue with donor restrictions and then released from restriction.

Conditional contributions and investment income having donor stipulations which are satisfied in the period the gift is received and the investment income is earned are recorded as revenue with donor restrictions and then released from restriction.

Contributed Nonfinancial Assets

Contributed nonfinancial assets are recorded at their estimated fair values on the date received. For the years ended June 30, 2025 and 2024, contributed nonfinancial assets recognized within the statements of activities included:

	<u>2025</u>	<u>2024</u>
Services	\$ 567,366	\$ 127,788
Other	<u>7,125</u>	<u>2,247</u>
	<u>\$ 574,491</u>	<u>\$ 130,035</u>

Unless otherwise noted, contributed nonfinancial assets did not have donor-imposed restrictions. Donated services are reported at the estimated fair value in the financial statements on current rate for similar services and were utilized by PanCAN's program services.

Other consists of contributed gift cards, food, and supplies that were utilized in PanCAN's PurpleStride fundraising event. PanCAN estimated the fair value based on estimates of wholesale values that would be received for selling similar products.

Income Taxes

PanCAN is exempt from income taxes under Section 501 of the Internal Revenue Code and similar provision of state law. However, PanCAN is subject to federal income tax on any unrelated business taxable income. PanCAN files tax returns in the U.S. federal jurisdiction.

PanCAN follows accounting requirements related to uncertain tax positions. Tax positions taken may include positions that PanCAN is exempt from income taxes or how PanCAN determines its unrelated business income. Uncertain tax positions are recognized if it is more likely than not, based on the technical merits, that the tax position will be realized or sustained upon an examination by the relevant tax authority. No amounts have been recorded at June 30, 2025 and 2024 with respect to uncertain tax positions.

Functional Allocation of Expenses

The costs of supporting the various programs and other activities have been summarized on a functional basis in the statements of activities. The statements of functional expenses presents the natural classification detail of expenses by function. Certain costs have been allocated among the program and management and general categories based on estimates of time incurred, usage, and other relevant factors.

Note 2. Investments and Fair Value Measurements

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs. The hierarchy comprises three levels of inputs that may be used to measure fair value:

- Level 1** Quoted prices in active markets for identical assets or liabilities
- Level 2** Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
- Level 3** Unobservable inputs supported by little or no market activity and that are significant to the fair value of the assets or liabilities

Recurring Measurements

The following tables present the fair value measurements of assets recognized in the accompanying statements of financial position measured at fair value on a recurring basis and the level within the fair value hierarchy in which the fair value measurements fall at June 30, 2025 and 2024:

		Fair Value Measurements Using		
		Quoted Prices in Active Market for Identical Assets (Level 1)	Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
	Total Fair Value			
June 30, 2025				
Assets				
Fixed income securities				
Corporate bonds	\$ 3,948,051	\$ -	\$ 3,948,051	\$ -
U.S. Treasuries	2,845,381	2,845,381	-	-
Mutual funds				
Equity funds	1,718,408	1,718,408	-	-
Corporate bonds	4,425,044	4,425,044	-	-
Exchange traded funds	681,165	681,165	-	-
Common stock	4,536,010	4,536,010	-	-
Other assets – REIT	85,483	85,483	-	-
Total investments reported on the fair value hierarchy				
	<u>\$ 18,239,542</u>	<u>\$ 14,291,491</u>	<u>\$ 3,948,051</u>	<u>\$ -</u>

Pancreatic Cancer Action Network
Notes to Financial Statements
June 30, 2025 and 2024

		Fair Value Measurements Using		
		Quoted Prices in Active Market for Identical Assets (Level 1)	Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
	Total Fair Value			
June 30, 2024				
Assets				
Fixed income securities				
Corporate bonds	\$ 11,244,920	\$ -	\$ 11,244,920	\$ -
U.S. Treasuries	5,289,133	5,289,133	-	-
Mortgage pools	447,996	-	447,996	-
Mutual funds				
Equity funds	3,034,588	3,034,588	-	-
Exchange traded funds	2,985,553	2,985,553	-	-
Common stock	6,970,817	6,970,817	-	-
Other assets – REIT	92,478	92,478	-	-
Total investments reported on the fair value hierarchy	<u>\$ 30,065,485</u>	<u>\$ 18,372,569</u>	<u>\$ 11,692,916</u>	<u>\$ -</u>

Following is a description of the valuation methodologies and inputs used for assets measured at fair value on a recurring basis and recognized in the accompanying statement of financial position, as well as the general classification of such assets pursuant to the valuation hierarchy. There have been no significant changes in the valuation techniques during the years ended June 30, 2025 and 2024.

Investments

Where quoted market prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available, then fair values are estimated by using quoted prices of securities with similar characteristics or independent asset pricing services and pricing models, the inputs of which are market-based or independently sourced market parameters, including, but not limited to, yield curves, interest rates, volatilities, prepayments, defaults, cumulative loss projections, and cash flows. Such securities are classified in Level 2 of the valuation hierarchy. In certain cases where Level 1 or Level 2 inputs are not available, securities are classified within Level 3 of the hierarchy. No Level 3 securities were held for the years ended June 30, 2025 and 2024.

Note 3. Grant Obligations

Grant obligations consist of annual award installments and administrative fees due on multi-year research grants that are payable each year in advance, over one to three years. During the year ended June 30, 2024, PanCAN awarded new grant obligations in the amount of \$125,000. No new grant obligations were awarded in 2025.

Pancreatic Cancer Action Network
Notes to Financial Statements
June 30, 2025 and 2024

Future payments on grant obligations consisted of the following:

<u>Year Ending June 30, 2025</u>	<u>General Grant Obligations</u>	<u>Clinical Trial Obligations</u>	<u>Total</u>
2026	\$ 1,962,207	\$ 290,415	\$ 2,252,622
	1,962,207	290,415	2,252,622
Less discounts	(27,768)	-	(27,768)
	<u>\$ 1,934,439</u>	<u>\$ 290,415</u>	<u>\$ 2,224,854</u>

Note 4. Pledges Receivable

PanCAN received promises to give. Noncurrent pledges receivable have been discounted over the payment period using a risk-free discount rate ranging from 2.31% to 4.52% for the year ended June 30, 2025 and 4.43% to 5.09% for the year ended June 30, 2024. Pledges receivables are due as follows:

	<u>2025</u>	<u>2024</u>
Due within one year	\$ 7,651,982	\$ 7,086,244
Due within one to six years	5,472,000	8,216,702
	<u>13,123,982</u>	<u>15,302,946</u>
Less		
Allowance for uncollectible pledges	(350,989)	(202,486)
Unamortized discount	<u>(823,992)</u>	<u>(1,098,064)</u>
	<u>\$ 11,949,001</u>	<u>\$ 14,002,396</u>

Note 5. Property and Equipment

Property and equipment at June 30, 2025 and 2024 consisted of:

	<u>2025</u>	<u>2024</u>
Furniture and equipment	\$ 237,786	\$ 412,452
Computer hardware and software	991,852	881,031
Database system and website	3,378,698	3,378,698
Leasehold improvements	297,674	895,054
Construction in progress	-	483,828
	<u>4,906,010</u>	<u>6,051,063</u>
Accumulated depreciation	<u>(4,311,622)</u>	<u>(5,401,548)</u>
	<u>\$ 594,388</u>	<u>\$ 649,515</u>

Note 6. Revenue from Contracts with Customers

Clinical Trials and Fees

PanCAN contracts directly with pharmaceutical/biotech companies (customers) to conduct clinical trials for pancreatic cancer patients. The clinical trials are generally billed and paid based on achievement of milestones or set timeframes (e.g., quarterly, etc.). The performance obligation under clinical trials are typically billed one month to one quarter in arrears, which may result in an unbilled service asset or contract asset at period-end.

At contract inception, PanCAN and the customer design the scope of work for the services to be provided and the deliverables bargained for in the contract. Contracts entered into for clinical trials are considered a single performance obligation as PanCAN provides a highly integrated service resulting in a combined output which is the final end result of the clinical trial (whether it results in a successful or terminated trial).

Revenue is recognized for the single performance obligation over time due to PanCAN's right to payment for work performed to date. The contracts enable PanCAN to invoice the customer as work progresses based on the corresponding milestones during the life cycle of a clinical trial.

Contracts are terminable by the customer, according to advance notice terms, medical, scientific, or safety reasons, or specific terms of breach specified within the contracts. If a contract is terminated, payment of fees for services rendered through the date of termination is required and may require payment for subsequent services necessary to conclude the study or close out the contract. Final settlement amounts are agreed to with the customer based on remaining work to be performed. These amounts are included in revenue when PanCAN believes the amount can be estimated reliably and its realization is probable. In evaluating the probability of recognition, PanCAN considers the contractual basis for the settlement amount and the objective evidence available to support the amount.

PanCAN is in the process of winding down its clinical trials program. As existing contracts has reached completion, PanCAN is working closely with customers to ensure all remaining obligations are fulfilled, including final milestone billing, settlement of outstanding fees, and completion of required closeout activities. The organization is committed to maintaining transparency and compliance throughout the wind-down period, and any final settlements or adjustments will be recognized in revenue when reliably estimable and probable, consistent with PanCAN's revenue recognition policy.

Transaction Price and Recognition

PanCAN determines the transaction price based on PanCAN's internal pricing guidelines, and negotiations with the customer. The transaction price is the contractually defined amount that includes adjustment for variable consideration, such as study stages, percent of subject enrollment or retainage on periodic billings, which are estimable. The progression of contract performance obligations are measured primarily utilizing an estimate of percentage completion based upon the "level of effort" (stage in the clinical trial life cycle).

From time to time, PanCAN will receive overpayments of customer balances resulting in amounts owed back to third parties. These amounts are excluded from revenues and are recorded as liabilities until they are refunded. As of June 30, 2024, PanCAN held a refund liability of \$372,663 as a result of overpayments of customer balances. PanCAN did not have any overpayments or related liabilities as of June 30, 2025.

Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to revenue in the period of the change. For the years ended June 30, 2025 and June 30, 2024, additional revenue \$154,737 and \$1,927,895, respectively, was recognized due to changes in estimates of transaction prices for performance obligations satisfied in prior years. Subsequent changes that are determined to be the result of an adverse change in the customer's ability to pay are recorded as credit loss expense. For the year ended June 30, 2025 no additional revenue was recognized due to change in transaction price.

Pancreatic Cancer Action Network
Notes to Financial Statements
June 30, 2025 and 2024

PanCAN has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the payors that have different reimbursement and payment methodologies. All clinical trial revenue is recognized over time.

Contract Balances

The following table provides information about PanCAN's receivables from contracts, contract assets and contract liabilities with customers:

	<u>2025</u>	<u>2024</u>
Accounts receivable, beginning of year	\$ 128,847	\$ 4,922,892
Accounts receivable, end of year	\$ 435,868	\$ 128,847
Contracts in progress, beginning of year	\$ 92,321	\$ 4,321,679
Contracts in progress, end of year	\$ -	\$ 92,321
Deferred revenue, beginning of year	\$ 1,144,084	\$ 1,074,901
Deferred revenue, end of year	\$ 30,540	\$ 1,144,084

Note 7. Net Assets

Net Assets with Donor Restriction

Net assets with donor restrictions at June 30 are restricted for the following purposes or periods:

	<u>2025</u>	<u>2024</u>
Subject to expenditure for specified purpose		
Research	\$ 10,297,546	\$ 16,232,151
Patient services	704,205	610,000
SPARK Health Data Platform	280,000	300,000
	<u>11,281,751</u>	<u>17,142,151</u>
Subject to passage of time		
Promises to give that are not restricted by donors but which are unavailable for expenditure until due	<u>4,552,884</u>	<u>1,789,414</u>
	<u><u>\$ 15,834,635</u></u>	<u><u>\$ 18,931,565</u></u>

Pancreatic Cancer Action Network
Notes to Financial Statements
June 30, 2025 and 2024

Net Assets Released from Restrictions

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes or occurrence of other events specified by donors.

	2025	2024
Expiration of time restrictions	\$ 1,963,928	\$ 791,920
Satisfaction of purpose restrictions		
Research	7,231,670	8,460,393
Advocacy	25,000	65,000
Patient services	296,795	1,319,737
SPARK Health Data Platform	221,000	100,000
	<u>\$ 9,738,393</u>	<u>\$ 10,737,050</u>

Note 8. Liquidity and Availability

As of June 30, 2025 and 2024, the following financial assets could readily be made available within one year of the statements of financial position date to meet general expenditures:

	2025	2024
Cash and cash equivalents	\$ 3,697,011	\$ 7,781,023
Investments	18,239,542	30,065,485
Pledges receivable, net	11,949,001	14,002,396
Receivables	435,868	128,847
	<u>34,321,422</u>	<u>51,977,751</u>
Less amounts not available to be used within one year due to		
Donor-restricted for purpose or time	(15,834,635)	(12,146,875)
Board-designated for operating reserve	<u>(5,649,708)</u>	<u>(17,090,000)</u>
	<u>\$ 12,837,079</u>	<u>\$ 22,740,876</u>

PanCAN receives significant contributions restricted by donors or grantors and considers contributions restricted for programs which are ongoing, major, and central to its annual operations to be available to meet cash needs for general expenditures. As of June 30, 2025 and 2024, restricted contributions receivable of \$6,000,292 and \$6,784,690, respectively, are due within the next year and was included in financial assets available to meet cash needs for general expenditures within one year.

The board-designated operating reserve is without donor restrictions that has been designated for use in emergencies and to sustain financial operations in the event budgeted revenue is not realized or unforeseen expenses are incurred. The Board has established a target of maintaining a minimum, fully funded operating reserve sufficient to fund four months of budgeted operating costs.

PanCAN manages its liquidity and reserves following three guiding principles: operating within a prudent range of financial soundness and stability, maintaining adequate liquid assets to fund near-term operating needs, and maintaining sufficient reserves to provide reasonable assurance that long-term obligations will be discharged. PanCAN monitors liquidity and cash flows on an ongoing basis to ensure an appropriate amount of cash and cash equivalents are available to meet current expenditure needs. Management reports its financial position regularly to different committees of the Board and to the whole Board.

Note 9. Leases

Accounting Policies

PanCAN determines if an arrangement is a lease or contains a lease at inception. Leases result in the recognition of right-of-use (ROU) assets and lease liabilities on the statement of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. PanCAN determines lease classification as operating or finance at the lease commencement date.

PanCAN accounts for the lease and nonlease components separately. The lease component consists of office space and nonlease components consist of common area maintenance charges. Lease and nonlease components are clearly defined on the monthly invoice, therefore, PanCAN allocates the consideration to the lease and nonlease components using their relative standalone values.

At lease commencement, the lease liability is measured at the present value of the lease payments over the lease term. The ROU asset equals the lease liability adjusted for any initial direct costs, prepaid or deferred rent, and lease incentives. PanCAN has made a policy election to use a risk-free rate (the rate of a zero-coupon U.S. Treasury instrument) for the initial and subsequent measurement of all lease liabilities. The risk-free rate is determined using a period comparable with the lease term.

The lease term may include options to extend or to terminate the lease that PanCAN is reasonably certain to exercise. Lease expense is generally recognized on a straight-line basis over the lease term.

PanCAN has elected not to record leases with an initial term of 12 months or less on the statement of financial position. Lease expense on such leases is recognized on a straight-line basis over the lease term.

Nature of Lease

PanCAN has entered into the following lease arrangements:

Operating Lease

During fiscal year 2025, PanCAN officially commenced a new lease with their landlord on October 1, 2024, for new office space. The new lease contains a right of renewal for one year that PanCAN is reasonably certain to exercise as a result of significant leasehold improvements being made. Lease payments on the new lease agreement have an escalating fee schedule, which is approximately 3% each year. Termination of the new lease is generally prohibited unless there is a violation under the lease agreement. PanCAN had an agreement in place with the landlord that when the new space became available, PanCAN was no longer required to make payments on the old lease space, effectively terminating the original lease on the date of the new lease.

During fiscal year 2025, the landlord of the original lease space amended the payments required on the lease, significantly reducing the monthly rent payments by approximately \$39,000 each month through the commencement of the new lease. As the new lease commencement date was unknown as of the lease modification date, PanCAN estimated the modified lease term to be through October 2026 which is consistent with the previous lease term. This resulted in a remeasurement of the ROU asset, lease liability, and discount rate on the old lease. The discount rate on the original lease increased from 0.52% to 4.76% and total payments to the end of the lease decreased by approximately \$1,388,000.

Pancreatic Cancer Action Network
Notes to Financial Statements
June 30, 2025 and 2024

Quantitative Disclosures

The lease cost and other required information for the years ended June 30, 2025 and 2024 are:

	<u>2025</u>	<u>2024</u>
Lease cost		
Operating lease cost	\$ 605,696	\$ 566,167
Other information		
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows from operating leases	\$ 412,326	\$ 754,394
Right-of-use assets obtained in exchange for new operating lease liabilities	\$ 4,448,697	\$ -
Weighted-average remaining lease term		
Operating leases	7.21 years	2.33 years
Weighted-average discount rate		
Operating leases	3.66%	4.76%

Future minimum lease payments and reconciliation to the statement of financial position at June 30, 2025 are as follows:

	<u>Operating Lease</u>
2026	\$ 629,749
2027	648,106
2028	653,624
2029	668,636
2030	688,695
Thereafter	<u>1,623,992</u>
Total future undiscounted lease payments	4,912,802
Less present value discount	<u>(605,887)</u>
Lease liability	<u>\$ 4,306,915</u>

Note 10. Retirement Plan

PanCAN has a 401(k) profit-sharing plan (the Plan) covering all eligible employees. The Plan provides for participants to make pre-tax contributions, with PanCAN matching 100% of contributions up to 3% of the participant's compensation and matching 50% of contributions for the next 2% of compensation. In addition, PanCAN may make discretionary additional contributions for its employees. During the years ended June 30, 2025 and 2024, PanCAN made nondiscretionary contributions of \$653,213 and \$767,785, respectively, toward its employees' 401(k) retirement accounts.

Note 11. Deferred Compensation Plans

In July 2015, PanCAN adopted a deferred compensation plan in accordance with Section 457(f) of the Internal Revenue Code. In September 2020, PanCAN adopted a deferred compensation plan in accordance with Section 457(b) of the Internal Revenue Code. The purpose of these plans is to offer certain eligible employees of PanCAN the opportunity to defer specified amounts of compensation on a pre-tax basis. During the years ended June 30, 2025 and 2024, PanCAN made nondiscretionary contributions of \$23,000 and \$22,500, respectively, to employees' 457(b) plans. During the year ended June 30, 2024, PanCAN made nondiscretionary contributions of \$75,000 to employees' 457(f) plans; no contributions were made during the year ended June 30, 2025. As of June 30, 2024, PanCAN held \$75,000 accrued under the deferred compensation plans. There were no amounts accrued for the year ended June 30, 2025.

Note 12. Significant Estimates and Concentrations

Accounting principles generally accepted in the United States of America require disclosure of certain significant estimates and current vulnerabilities due to certain concentrations. Those matters include the following:

Accounts Receivable

Estimates associated with the allowance for uncollectible receivables are discussed in Note 1.

Pledges Receivable

As of June 30, 2025 and 2024, approximately 47% and 79% of pledges receivable were due from one donor.

Contributions

For the years ended June 30, 2025 and 2024, approximately 38% and 37%, respectively, of total revenue was from special events. This represents concentration of risk to PanCAN due to the PurpleStride event.

Grant Obligations

As of June 30, 2025 and 2024, approximately 70% and 71%, respectively, of grant obligations were due to two grantees.

Investments

PanCAN invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such change could materially affect the amounts reported in the accompanying statements of financial position.

Functional Allocation of Expenses

Estimates used to allocate certain costs on a functional basis are discussed in Note 1 and Note 13.

Note 13. Allocation of Joint Costs

PanCAN hires consultants to assist in digital and physical direct mail campaigns. Campaign communications include information for three distinct categories: public education, program specific, and fundraising. Effective July 1, 2023, PanCAN updated its policy for allocation of functional expenses related to advertising campaigns. Expenses from the campaigns are allocated based on number of lines of content related to each of the three categories. The costs of conducting those activities were \$505,417 and \$385,823 for the years ended June 30, 2025 and 2024, which were categorized under general purpose, program specific, and fundraising. The joint costs were allocated as follows:

	2025		2024	
	Expenses	Average Allocation Percentage	Expenses	Average Allocation Percentage
Categories				
Public education	\$ 138,535	27%	\$ 161,004	42%
Program specific	78,542	16%	54,092	14%
Fundraising	288,340	57%	170,727	44%
Total joint costs	<u>\$ 505,417</u>		<u>\$ 385,823</u>	

Note 14. Subsequent Events

Subsequent events have been evaluated through October 24, 2025, which is the date the financial statements were available to be issued.

Effective August 13, 2025, PanCAN has established access to a margin facility with the financial institution that custodies its investment assets. The margin rate is the Federal Funds Rate plus 0.50%. The margin is collateralized by assets held with the financial institution. The margin facility enhances PanCAN's liquidity, however, PanCAN does not anticipate employing the margin facility.